Three Chinese Biotech IPOs Gross $639m In June

Activity Picks Up

 
• By Dexter Jie Yan

Genrix grossed $478.9m in the largest initial public offering from an innovative drug-focused biotech on Shanghai's STAR Market since February 2022. Meanwhile, Laekna and Cutia launched two smaller IPOs in Hong Kong.

China biotech IPO
June marked busy month for IPOs for Chinese innovative biotechs • Source: Shutterstock

More from China

More from Focus On Asia